Evidence map›Paper›PMID 33767384›Full record

Trial reportScientific reports2021

School-based screening and treatment may reduce P. falciparum transmission.

Lauren M Cohee, Clarissa Valim, Jenna E Coalson, Andrew Nyambalo, Moses Chilombe, Andrew Ngwira, Andy Bauleni, Karl B Seydel, Mark L Wilson, Terrie E Taylor and 2 more

3 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 18 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04858087 completednot on this map

Epidemiology of Malaria in Malawi: Human Hosts and Parasites in Three Districts Part 2: Cross-sectional Surveillance (School-based Cohorts)

TypeobservationalSponsorUniversity of Maryland, BaltimoreRan2015 to 2015Enrolled786ConditionsMalaria, Malaria,Falciparum, AnemiaArmsScreening and treatment
NCT05244954 phase4completednot on this mapstarted 2022, after this paper: background citation

Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2022 to 2022Enrolled746ConditionsMalaria,Falciparum, Anemia in ChildrenArmsDihydroartemisinin-Piperaquine, Chloroquine
NCT05980156 phase4completednot on this mapstarted 2023, after this paper: background citation

Clinical Trial to Evaluate Intermittent Screening and Treatment and Intermittent Preventive Treatment of Malaria in Asymptomatic Schoolchildren to Decrease P. Falciparum Infection and Transmission: Phase 2 Comparing Drug Regimens

TypeinterventionalSponsorUniversity of Maryland, BaltimoreRan2023 to 2023Enrolled646ConditionsMalaria,Falciparum, Anemia in ChildrenArmsDihydroartemisinin-Piperaquine, Chloroquine, Sulfadoxine pyrimethamine
3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 26 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Malaria prevention: advancing clinical trials to policy.The Lancet. Infectious diseases · 2024
    Article
  10. Article
  11. Article
  12. Article
  13. Diagnostic performance of NxTekMalaria journal · 2023
    Article
  14. Article
  15. Review
  16. Understanding the Intransigence of Malaria in Malawi.The American journal of tropical medicine and hygiene · 2022
    Article
  17. Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 2 countries.

Lauren M Cohee *Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201, USA. lcohee@som.umaryland.edu.
Clarissa Valim *Department of Global Health, Boston University School of Public Health, Boston, MA, USA.
Jenna E CoalsonDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Andrew NyambaloBlantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi.
Moses ChilombeMalaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.
Andrew NgwiraMalaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.
Andy BauleniMalaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.
Karl B SeydelBlantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi.
Mark L WilsonDepartment of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
Terrie E TaylorBlantyre Malaria Project, University of Malawi College of Medicine, Blantyre, Malawi.
Don P MathangaMalaria Alert Center, University of Malawi College of Medicine, Blantyre, Malawi.
Miriam K LauferCenter for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, MD, 21201, USA.
University of Malawi · MWUniversity of Maryland, Baltimore · USBoston University · USMichigan State University · USUniversity of Michigan–Ann Arbor · USUniversity of Notre Dame · US

Funding

The role of monocytes in the pathology of severe malaria.U19AI089683 · NIAID · MICHIGAN STATE UNIVERSITY · PI MATENGENI, ALFRED · 2010 to 2023
$21.4M
Mentoring in patient-oriented research in global healthK24AI114996 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI LAUFER, MIRIAM K. · 2016 to 2025
$1.6M
Impact of P. falciparum diversity on transmission reducing immunityK23AI135076 · NIAID · UNIVERSITY OF MARYLAND BALTIMORE · PI COHEE, LAUREN M · 2018 to 2022
$940k
NIAID NIH HHS K23 AI135076NIAID NIH HHS K24 AI114996NIAID NIH HHS U19 AI089683
6 · The paper itself

Abstract

In areas where malaria remains entrenched, novel transmission-reducing interventions are essential for malaria elimination. We report the impact screening-and-treatment of asymptomatic Malawian schoolchildren (n = 364 in the rainy season and 341 in the dry season) had on gametocyte-the parasite stage responsible for human-to-mosquito transmission-carriage. We used concomitant household-based surveys to predict the potential reduction in transmission in the surrounding community. Among 253 students with P. falciparum infections at screening, 179 (71%) had infections containing gametocytes detected by Pfs25 qRT-PCR. 84% of gametocyte-containing infections were detected by malaria rapid diagnostic test. While the gametocyte prevalence remained constant in untreated children, treatment with artemether-lumefantrine reduced the gametocyte prevalence (p < 0.0001) from 51.8 to 9.7% and geometric mean gametocyte density (p = 0.008) from 0.52 to 0.05 gametocytes/microliter. In community surveys, 46% of all gametocyte-containing infections were in school-age children, who comprised only 35% of the population. Based on these estimates six weeks after the intervention, the gametocyte burden in the community could be reduced by 25-55% depending on the season and the measure used to characterize gametocyte carriage. Thus, school-based interventions to treat asymptomatic infections may be a high-yield approach to not only improve the health of schoolchildren, but also decrease malaria transmission.

Indexed as

AntimalarialsArtemether, Lumefantrine Drug CombinationChildCohort StudiesFemaleHumansMalaria, FalciparumMalawiMaleMass ScreeningPlasmodium falciparumSchool Health ServicesAntimalarialsArtemether, Lumefantrine Drug Combination

Identifiers

PMID33767384
PMCPMC7994823
OpenAlexW3137173841

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.